Crossmark

Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy

Crossref DOI link: https://doi.org/10.1038/s41587-019-0073-7

Published Online: 2019-04-01

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kang, Jeffrey C.

Sun, Wei

Khare, Priyanka

Karimi, Mostafa

Wang, Xiaoli

Shen, Yang http://orcid.org/0000-0002-1703-7796
Ober, Raimund J. http://orcid.org/0000-0002-1290-7430
Ward, E. Sally http://orcid.org/0000-0002-9311-8571
License Information

Text and Data Mining valid from 2019-04-01
More Information

Article History

Received: 6 September 2018

Accepted: 20 February 2019

First Online: 1 April 2019

Competing interests

: J.C.K., W.S., R.J.O. and E.S.W. are co-inventors on a pending patent (PCT/US2018/013952) describing acid-switched ADCs.